Atopic Dermatitis Treatment Market Research Report Information By Drug Class (Biologics, PDE4 Inhibitors), By Route Of Administration (Topical, Injectable, Oral), And By Region (North America, Europe, Asia-Pacific, And Rest of The World) –Market Forecast Till 2032

Atopic Dermatitis Treatment Market Overview

Atopic Dermatitis Treatment Market Size was valued at USD 15.2 Billion in 2022. The Atopic Dermatitis Treatment Market industry is projected to grow from USD 16.9 Billion in 2023 to USD 40.81 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.60% during the forecast period (2024 - 2032). The increase in the incidences of atopic dermatitis (AD) among populations across the globe, the growth in awareness regarding the availability of treatments for the disease among people, and the increase in initiatives undertaken by governments to provide better and more affordable treatment are expected to be a significant market driver for the Atopic Dermatitis Treatment Market.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Atopic Dermatitis Treatment Market Trends

• 
  

  Increasing burden of allergic reactions, an important role played by food allergy, and increasing environmental pollution are driving the market growth

  
  

Market CAGR for Atopic Dermatitis Treatment is driven by the increasing burden of allergic reactions, an important role played by food allergy, and increasing environmental pollution. The expanding prevalence of allergic reactions, notably in the context of food allergies, is a key driver for market growth. According to the 2020 Food Allergy Research and Education (FARA) report, an estimated 32 million residents in the United States, including 5.6 million children under 18, have food allergies, with 40% of affected children allergic to multiple foods. Similarly, the Australian Society of Clinical Immunology and Allergy (ASCIA) reported in May 2021 that food allergy affects approximately 10% of infants, 4-8% of children, and 2% of adults in Australia and New Zealand.

Furthermore, a Nutrition Today Journal article from February 2020 highlighted food allergy as a significant   public health concern, affecting an estimated 3% to 10% of adults and 8% of children worldwide. The National Center for Biotechnology Information (NCBI) underscored in a June 2020 article that infants with temporary skin barrier disruption and persistent atopic dermatitis are particularly vulnerable to developing food allergies. The study revealed that one-third of severe atopic dermatitis cases with positive symptoms were observed in patients undergoing an oral food challenge. Additionally, many children with atopic dermatitis exhibit asymptomatic sensitization to foods. The interconnected relationship between food allergies and atopic dermatitis is expected to drive increased demand for atopic dermatitis treatments  ly, thereby fueling market growth.

As a result, it is anticipated that throughout the projection period, demand for the Atopic Dermatitis Treatment Market will increase due to t the increasing burden of allergic reactions, an important role played by food allergy, and increasing environmental pollution. Thus, driving the Atopic Dermatitis Treatment Market revenue.

Atopic Dermatitis Treatment Market Segment Insights

Atopic Dermatitis Treatment Market Drug Class Insights

The Atopic Dermatitis Treatment Market segmentation, based on Drug Class includes Biologics and PDE4 Inhibitors. The Biologics segment dominated the market, accounting for 58% of market revenue (8.8 Billion). Biological therapy holds a substantial market share and entails the utilization of substances derived from living organisms for treating atopic dermatitis. These therapies typically focus on specific molecules or pathways within the inflammatory response linked to the condition. Examples include monoclonal antibodies and other biologics designed to modulate the immune system. The significant market share underscores the increasing preference for targeted and personalized approaches. Biological therapies aim to tackle the underlying causes of atopic dermatitis, providing enhanced efficacy and potentially fewer side effects compared to traditional treatments.

Figure 1:   Atopic Dermatitis Treatment Market, by Drug Class, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Atopic Dermatitis Treatment Market Route of Administration Insights

The Atopic Dermatitis Treatment Market segmentation, based on the Route of Administration includes Topical, Injectable, and Oral. The Injectable segment dominated the market, accounting for 58% of market revenue. The injectable segment has been the dominant force in the market, and this trajectory is anticipated to persist throughout the forecast period, driven by a surge in product approvals, exemplified by drugs like dupilumab. The introduction of Dupixent in 2017 marked a significant milestone in the injectables segment. Additionally, healthcare professionals are increasingly prescribing corticosteroids through injections to expedite their effects on patients.

Atopic Dermatitis Treatment Market Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The anticipated expansion of the Atopic Dermatitis Treatment market in North America can be attributed to several key factors. Improved reimbursement policies, growing pharmaceutical company collaborations with contract research organizations in emerging markets, and advancements in product development are driving the market's expansion. For instance, in February 2022, Evelo Biosciences, Inc., announced the dosing of the first patient in EDP1815-207, a Phase 2 randomized clinical trial evaluating EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis. Additionally, in February 2021, the United States Food and Drug Administration (USFDA) granted Priority Review to the New Drug Application (NDA) for Ruxolitinib Cream, a selective JAK1/JAK2 inhibitor developed by Incyte Corporation for topical application in treating atopic dermatitis. Furthermore, the escalating investments in atopic dermatitis are anticipated to contribute significantly to the region's growth. As per a National Health Institutes (NIH) article published in June 2021, the estimated funding for atopic dermatitis research was USD 46 million in 2021 and USD 44 million in 2022.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Atopic Dermatitis Treatment Market Share By Region 2023 (Usd Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Atopic Dermatitis Treatment Market accounts for the second-largest market share as Atopic dermatitis/eczema is recognized as the most prevalent inflammatory skin disease, impacting approximately 20% of children and adolescents  ly. According to the International Study of Asthma and Allergies in Childhood (ISAAC), estimates suggest that atopic dermatitis/eczema affects 15% to 20% of children and 1% to 3% of adults worldwide. The onset of atopic dermatitis/eczema commonly occurs in early childhood and may persist into adulthood. As awareness of the condition grows and more individuals seek medical intervention, the Atopic Dermatitis Treatment Market is likely to witness increased demand for therapies and pharmaceutical solutions, driving market growth. Additionally, advancements in research and development, coupled with a focus on innovative treatment modalities, are expected to further enhance the market's expansion. Further, the German Atopic Dermatitis Treatment Market held the largest market share, and the UK Atopic Dermatitis Treatment Market was the fastest-growing market in the European region

The Asia-Pacific Atopic Dermatitis Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. The atopic dermatitis market in Asia-Pacific has experienced remarkable growth, driven by the region's robust healthcare technology, a substantial patient demographic, and an increase in healthcare spending. Notably, in China, among 369 diseases, atopic dermatitis ranked twenty-fourth in terms of age-standardized Years Lived with Disability (YLD) rate. The period from 1990 to 2019 witnessed a rapid increase (1.43%) in the number of atopic dermatitis patients and Years Lived with Disability (YLD) in China, attributed to both population growth and aging. This dynamic growth in the atopic dermatitis market in the Asia-Pacific region underscores the region's significant market potential and evolving healthcare landscape. Moreover, China’s Atopic Dermatitis Treatment Market held the largest market share, and the Indian Atopic Dermatitis Treatment Market was the fastest-growing market in the Asia-Pacific region.

Atopic Dermatitis Treatment Market Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Atopic Dermatitis Treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Atopic Dermatitis Treatment industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the   Atopic Dermatitis Treatment industry to benefit clients and increase the market sector. In recent years, the Atopic Dermatitis Treatment industry has offered some of the most significant advantages to the healthcare sector and patients alike. Major players in the Atopic Dermatitis Treatment Market, including AbbVie Inc., Arcutis Biotherapeutics, Inc., Asana Biosciences, Inc., Astellas Pharma, Inc., Bayer AG, Inc., Bristol-Myers Squibb Inc., Dermavant Sciences, Inc., Eli Lilly and Company, Inc., Galderma, Inc., Incyte Corporation, Inc are attempting to increase market demand by investing in research and development operations.

AbbVie Inc. operates as a specialized biopharmaceutical company, dedicated to the discovery, development, manufacturing, and commercialization of drugs targeting chronic and intricate diseases. Its pharmaceuticals cater to conditions such as metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, endometriosis-associated pain, pediatric Crohn's disease, cancer, and various other severe health issues. AbbVie is actively progressing its pipeline initiatives for Crohn's disease, Parkinson's disease, viral diseases, wet AMD, diverse cancers, neurological disorders, aesthetics, and autoimmune diseases. The company distributes its products  ly directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers through its distribution centers and public warehouses. Headquartered in North Chicago, Illinois, AbbVie announced in January 2022 the U.S. FDA approval of RINVOQ (upadacitinib) for the management of severe atopic dermatitis in individuals aged 12 and above. RINVOQ is recommended for patients unresponsive to prior treatments involving injections and oral medications.

Sanofi operates as a healthcare company, actively involved in the exploration, development, production, and promotion of a diverse range of medicines and vaccines. Its comprehensive portfolio encompasses medications for cancer, rare diseases, and multiple sclerosis, as well as human vaccines protecting against various bacterial and viral infections, among other products. Additionally, Sanofi offers consumer healthcare items addressing digestion, allergy, cough, cold, flu, sinus, pain, women’s health, and vitamins, minerals, and supplements. The company is dedicated to research and development efforts aimed at enhancing the efficacy of treatments through combination drugs and formulating new biologics to create precision medicines. With a   presence spanning Europe, the Americas, Asia-Pacific, Africa, and the Middle East, Sanofi is headquartered in Paris, Ile-de-France, France. In June 2022, Sanofi achieved U.S. FDA approval for Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, whose condition is not adequately controlled with topical prescription therapies or when such therapies are not recommended.

Key companies in the Atopic Dermatitis Treatment Market include

• AbbVie Inc.


• Arcutis Biotherapeutics, Inc.


• Asana Biosciences, Inc.


• Astellas Pharma, Inc.


• Bayer AG, Inc.


• Bristol-Myers Squibb Inc.


• Dermavant Sciences, Inc.


• Eli Lilly and Company, Inc.


• Galderma, Inc.


• Incyte Corporation, Inc.

Atopic Dermatitis Treatment Industry Developments

April 2021: In April 2021, AbbVie extended the evaluation period for RINVOQ, intended for adults and adolescents with atopic dermatitis, through a supplemental new drug application (NDA). The PDUFA timeline was extended until the third quarter of 2021.

September 2023: In September 2023, Arcutis Biotherapeutics filed a supplemental new drug application with the FDA for roflumilast cream (Zoryve). Initially sanctioned for atopic dermatitis in patients aged 6 and above, this cream is currently under review for the treatment of plaque psoriasis in the United States

Atopic Dermatitis Treatment Market Segmentation

Atopic Dermatitis Treatment Drug Class Outlook

• Biologics


• PDE4 Inhibitors

Atopic Dermatitis Treatment Route of Administration Outlook

• Topical


• Injectable


• Oral

Atopic Dermatitis Treatment Regional Outlook

• 
  
  Middle East
  
  


• 
  
  Africa
  
  


• 
  
  Latin America